Literature DB >> 3123483

Interaction of tissue-type plasminogen activator and plasminogen activator inhibitor 1 on the surface of endothelial cells.

Y Sakata1, M Okada, A Noro, M Matsuda.   

Abstract

The site of the reaction between plasminogen activators and plasminogen activator inhibitor 1 (PAI-1) was investigated in cultures of human umbilical vein endothelial cells. In conditioned medium from endothelial cells, two forms of a plasminogen activator-specific inhibitor can be demonstrated: an active form that readily binds to and inhibits plasminogen activators and an immunologically related quiescent form which has no anti-activator activity but which can be activated by denaturation. In conditioned medium, only a few percent of PAI-1 is the active form. However, the addition of increasing concentrations of tissue-type plasminogen activator (t-PA) or urokinase to confluent endothelial cells produced a saturable (3.0 pmol/5 x 10(5) cells), dose-dependent increase of the activator-PAI-1 complex in the conditioned medium even in the presence of actinomycin D or cycloheximide. This resulted also in a dose-dependent decrease of the residual PAI activity measured by reverse fibrin autography both in the conditioned medium and cell extracts. Short-time exposure of endothelial cells to a large amount of t-PA caused almost complete depletion of all cell-associated PAI activity. Although there was no detectable PAI activity even after activation of PAI by denaturants or antigen in the culture medium at 4 degrees C without the addition of t-PA, the addition of t-PA at 4 degrees C not only resulted in the formation of 70% of the amount of the t-PA.PAI complex in conditioned medium at 37 degrees C, but also induced PAI-1 antigen in a time and dose-dependent manner in the conditioned medium. Moreover, 125I-labeled t-PA immobilized on Sepharose added directly to endothelial cells formed a complex with PAI-1 in a dose-dependent manner. On the other hand, no detectable complex was formed with PAI-1 when Sepharose-immobilized 125I-labeled t-PA was added to endothelial cells under conditions in which the added t-PA could not contact the cells directly but other proteins could pass freely by the use of a Transwell. All these results suggest that a "storage pool" on the surface of endothelial cells or the extracellular matrix produced by endothelial cells contains almost all the active PAI-1, and reaction between PA and PAI-1 mainly occurs on the endothelial cell membranes, resulting in a decrease of the conversion of active PAI-1 to the quiescent form.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3123483

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

1.  IL-1-induced procoagulant and fibrinolytic activities of human endothelium grown on carbodiimide crosslinked proteins.

Authors:  R Warocquier-Clérout; J Penhoat; M F Sigot-Luizard
Journal:  Cytotechnology       Date:  1991-11       Impact factor: 2.058

2.  Human endotrophin as a driver of malignant tumor growth.

Authors:  Dawei Bu; Clair Crewe; Christine M Kusminski; Ruth Gordillo; Alexandra L Ghaben; Min Kim; Jiyoung Park; Hui Deng; Wei Xiong; Xiao-Zheng Liu; Per Eystein Lønning; Nils Halberg; Adan Rios; Yujun Chang; Anneliese Gonzalez; Ningyan Zhang; Zhiqiang An; Philipp E Scherer
Journal:  JCI Insight       Date:  2019-03-21

3.  Binding of tissue plasminogen activator to human aortic endothelial cells.

Authors:  M A Sanzo; S C Howard; A J Wittwer; H M Cochrane
Journal:  Biochem J       Date:  1990-07-15       Impact factor: 3.857

4.  alpha 2-Antiplasmin and plasminogen activator inhibitors in healing human skin wounds.

Authors:  B M Schaefer; K Maier; U Eickhoff; M Bechtel; M D Kramer
Journal:  Arch Dermatol Res       Date:  1996-03       Impact factor: 3.017

5.  Plasminogen activator inhibitor-1 deposition in the extracellular matrix of cultured human mesangial cells.

Authors:  J Hagège; M N Peraldi; E Rondeau; C Adida; F Delarue; R Medcalf; W D Schleuning; J D Sraer
Journal:  Am J Pathol       Date:  1992-07       Impact factor: 4.307

6.  Plasminogen-activator inhibitor type 1 is a potent natural inhibitor of extracellular matrix degradation by fibrosarcoma and colon carcinoma cells.

Authors:  J F Cajot; J Bamat; G E Bergonzelli; E K Kruithof; R L Medcalf; J Testuz; B Sordat
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

7.  Expression profiles of fibrinolytic components in nasal mucosa.

Authors:  Takayuki Sejima; Seiji Madoiwa; Jun Mimuro; Teruko Sugo; Takashi Ishida; Keiichi Ichimura; Yoichi Sakata
Journal:  Histochem Cell Biol       Date:  2004-06-12       Impact factor: 4.304

8.  Immunoelectron microscopic localization of type 1 plasminogen activator inhibitor on the surface of activated endothelial cells.

Authors:  R R Schleef; D J Loskutoff; T J Podor
Journal:  J Cell Biol       Date:  1991-06       Impact factor: 10.539

9.  The majority of type 1 plasminogen activator inhibitor associated with cultured human endothelial cells is located under the cells and is accessible to solution-phase tissue-type plasminogen activator.

Authors:  R R Schleef; T J Podor; E Dunne; J Mimuro; D J Loskutoff
Journal:  J Cell Biol       Date:  1990-01       Impact factor: 10.539

10.  Transforming growth factor-beta 1 modulates basic fibroblast growth factor-induced proteolytic and angiogenic properties of endothelial cells in vitro.

Authors:  M S Pepper; D Belin; R Montesano; L Orci; J D Vassalli
Journal:  J Cell Biol       Date:  1990-08       Impact factor: 10.539

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.